Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL – Get Rating) – Investment analysts at Wedbush lifted their Q2 2022 EPS estimates for shares of Zentalis Pharmaceuticals in a report released on Tuesday, May 10th. Wedbush analyst R. Driscoll now forecasts that the company will post earnings per share of ($1.08) for the quarter, up from their previous estimate of ($1.13). Wedbush has a “Outperform” rating and a $51.00 price objective on the stock. Wedbush also issued estimates for Zentalis Pharmaceuticals’ Q3 2022 earnings at ($1.10) EPS, Q4 2022 earnings at ($1.12) EPS, FY2022 earnings at ($4.54) EPS, FY2023 earnings at ($4.39) EPS, FY2024 earnings at ($4.25) EPS, FY2025 earnings at ($2.04) EPS and FY2026 earnings at $1.16 EPS.
Other equities analysts also recently issued reports about the stock. Oppenheimer dropped their target price on shares of Zentalis Pharmaceuticals from $100.00 to $85.00 and set an “outperform” rating on the stock in a research note on Tuesday, April 12th. Stifel Nicolaus dropped their target price on shares of Zentalis Pharmaceuticals from $94.00 to $74.00 in a research note on Monday, April 11th. Guggenheim dropped their target price on shares of Zentalis Pharmaceuticals from $92.00 to $67.00 in a research note on Wednesday, April 13th. Zacks Investment Research downgraded shares of Zentalis Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, April 22nd. Finally, Wells Fargo & Company initiated coverage on shares of Zentalis Pharmaceuticals in a research note on Wednesday, April 6th. They issued an “overweight” rating and a $67.00 target price on the stock. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Buy” and an average price target of $72.11.
Zentalis Pharmaceuticals (NASDAQ:ZNTL – Get Rating) last posted its quarterly earnings data on Thursday, May 5th. The company reported ($1.31) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.21) by ($0.10). During the same period in the prior year, the firm earned ($1.24) EPS.
Large investors have recently bought and sold shares of the stock. Parallel Advisors LLC purchased a new stake in Zentalis Pharmaceuticals during the fourth quarter valued at approximately $47,000. Fieldpoint Private Securities LLC purchased a new position in shares of Zentalis Pharmaceuticals in the fourth quarter worth $76,000. Dark Forest Capital Management LP purchased a new position in shares of Zentalis Pharmaceuticals in the third quarter worth $79,000. Advisor Group Holdings Inc. raised its holdings in shares of Zentalis Pharmaceuticals by 1,082.5% in the fourth quarter. Advisor Group Holdings Inc. now owns 1,218 shares of the company’s stock worth $102,000 after buying an additional 1,115 shares during the last quarter. Finally, IFP Advisors Inc purchased a new position in shares of Zentalis Pharmaceuticals in the fourth quarter worth $102,000. 95.01% of the stock is owned by institutional investors.
In related news, SVP Dimitris Voliotis sold 601 shares of the stock in a transaction that occurred on Monday, February 14th. The shares were sold at an average price of $50.23, for a total transaction of $30,188.23. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Melissa B. Epperly sold 1,913 shares of the stock in a transaction that occurred on Wednesday, February 23rd. The shares were sold at an average price of $49.10, for a total transaction of $93,928.30. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 122,836 shares of company stock worth $5,854,830. Insiders own 21.00% of the company’s stock.
About Zentalis Pharmaceuticals (Get Rating)
Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; Phase 1/2 clinical trial for the treatment of advanced solid tumors as a monotherapy and in an ongoing Phase 1b clinical trial in combination with chemotherapy in patients with platinum resistant ovarian cancer; and Phase 2 monotherapy trial for a tumor agnostic, predictive biomarker.
- Get a free copy of the StockNews.com research report on Zentalis Pharmaceuticals (ZNTL)
- Is Electronic Arts (NASDAQ: EA) Suddenly A Safe Haven?
- Beyond Meat Stock Value is Improving
- The Travel Sector Is Getting Upgraded
- Carvana Insiders Buy Shares But Maybe You Shouldn’t
- Dutch Bros Gets Scalded By Inflation
Receive News & Ratings for Zentalis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zentalis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.